Paradigm signs contract with Stratose for personalized medicine service
Paradigm, a molecular information and Next Generation Sequencing corporation specializing in providing cancer testing for patients with cancer, announced that it has entered into a contractual agreement with Stratose for coverage of PCDx.
PCDx is a Next-Generation Sequencing (NGS) based diagnostic test that is designed to provide physicians and patients with a more targeted, personalized approach to cancer treatment by identifying the underlying genomic and proteomic alterations of a patients tumor’s DNA, RNA & Protein.
Dr. Robert Penny, MD, PhD, CEO of Paradigm, noted, “Through this contract, millions of Stratose client members and their treating clinicians will have access to this important oncology service and make possible more informed and individually tailored treatment strategies.”
Stratose, based in Atlanta, GA, maintains one of the largest and growing directly managed PPO networks in the U.S., including more than 850,000 direct and affiliate medical, dental and workers’ compensation provider contract. These members will now have access to Paradigm’s PCDx.